ACR 2017 Conference Correspondent

This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

The MONARCH trial showed that subcutaneous sarilumab was superior to adalimumab monotherapy in reducing disease activity and improving physical function in active rheumatoid arthritis. Patients who completed the initial double-blind phase in MONARCH continued to the open-label extension and received sarilumab monotherapy.

Although tocilizumab has been known to elevate serum lipid levels in patients with RA, its cardiovascular effects are unknown.

Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.

The analysis of the COMPACT trial sought to demonstrate noninferiority of tocilizumab alone versus tocilizumab plus methotrexate (MTX) in maintaining clinical response in patients with rheumatoid arthritis (RA) who achieve low disease activity (LDA) following treatment with tocilizumab plus MTX.

This retrospective analysis of the Optum One electronic health record (EHR) databases from various Integrated Delivery Networks (IDNs) and large group practices across the United States was conducted to examine the EHR reporting rates of several clinical measures among patients with rheumatoid arthritis (RA) who received a biologic or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

Previous clinical trials have demonstrated that tocilizumab monotherapy was superior to tumor necrosis factor inhibitor (TNFi) monotherapy and comparable to tocilizumab plus methotrexate (MTX).

This study explored the effects of sarilumab, an anti–interleukin-6Rα human monoclonal antibody, or placebo in combination with disease-modifying antirheumatic drugs (DMARDs) on fasting glucose and glycosylated hemoglobin (HbA1c) in diabetic and nondiabetic patients with rheumatoid arthritis (RA).

This study assessed the comparative effectiveness of the Janus kinase 1/2 inhibitors, tofacitinib and baricitinib, in patients with rheumatoid arthritis (RA) using a network meta-analysis and Cochrane systematic review of randomized controlled trials from 7 electronic databases and 2 trial registries.

A post hoc analysis of the head-to-head, randomized Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Subjects with Background Methotrexate (AMPLE) trial demonstrated that subcutaneous (SC) abatacept treatment showed improved efficacy versus SC adalimumab in patients with seropositive, erosive early rheumatoid arthritis (RA).

Page 1 of 2
Results 1 - 10 of 19
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology